Screener
Avalo Therapeutics AVTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's cash & equivalents?
- Avalo Therapeutics (AVTX) reported cash & equivalents of $85.61M in Q2 2026.
- How has Avalo Therapeutics's cash & equivalents changed year-over-year?
- Avalo Therapeutics's cash & equivalents increased by 101.3% year-over-year, from $42.52M to $85.61M.
- What is the long-term trend for Avalo Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Avalo Therapeutics's cash & equivalents has grown at a -3.4% compound annual growth rate (CAGR), from $19.11M to $16.11M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Avalo Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude